Thursday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC

  • Federal News Network reports,
    • “The $350 billion defense reconciliation package is dead, but there is a path for a scaled-down version of the bill that would help fill “the hole in the defense budget that Venezuela and Iran have created,” Rep. Mike Rogers, the top Republican on the House Armed Services Committee, said.
    • “It looks like we are going to be able to get a reconciliation bill of some size, and by the way, $350 is not going to happen — you may have guessed that. But a reconciliation bill is still possible,” Rogers (R-Mich.) said Wednesday during a Hudson Institute event.
    • “Rogers said if the Trump administration manages to “skinny that reconciliation down from $350 billion down to $100 billion or somewhere in that nature, there is a path for that.” * * *
    • “Congress faces a looming funding deadline as the current continuing resolution is set to expire on Dec. 11, and the Republicans have about two weeks left in session before Democrats take control of both the House and Senate on Jan. 3.
    • So the appropriators are now “working on alternatives,” Rogers said.”
  • Radiology Buiness relates
    • “U.S. senators have introduced radiologist-supported legislation to stop certain insurers from reversing coverage for already-completed medical care. 
    • “Sens. Mark Kelly, D-Ariz., and John Kennedy, R-La., are proposing the Protecting Approved Care Act in the upper chamber. They note that Medicare Advantage plans frequently require preapproval for medical imaging or interventional procedures before they take place. 
    • However, insurers are increasingly green-lighting these prior authorizations, only to reverse their decision, deny coverage or demand repayment from physicians after patients receive care. 
    • “Insurance companies cannot have it both ways,” Sen. Kennedy said in a statement Nov. 17. “They shouldn’t be able to approve a patient’s medical care and then refuse to pay for it after doctors have done the work. Patients and doctors deserve better, and our bill would put an end to this unfair practice.” 
    • “Their proposal would prohibit Medicare Advantage plans from denying previously approved care, based on medical necessity. It also would protect physicians by stopping insurers from reopening coverage or payment decisions without cause. Plus, it would “stop unfair payment reductions” by preventing insurers from changing billing codes, along with extending other protections to medical services that don’t require prior authorization. 
  • BioPharma Dive points out,
    • “China’s five-year plan to strengthen its biotechnology industry and invent 25% of the world’s new drugs could allow the country to “corner the sector” and “leave American patients vulnerable to supply chain weaponization,” according to a report published Wednesday by a congressional commission.
    • “The report from the National Security Commission on Emerging Biotechnology endorsed a recent Treasury Department proposal to add biotech to the “COINS Act,” which could limit certain transactions with Chinese companies. But the commission also urged the government to “act now to empower the United States to out-innovate strategic competitors before it’s too late.”
    • “The commission’s report comes shortly after the Biotechnology Innovation Organization, a top industry lobbying group, unveiled a multifaceted plan to accelerate U.S. drug development and better compete with China going forward. More than 120 licensing deals between U.S. or European companies and Chinese drug developers have been struck since the start of 2025, according to BioPharma Dive data, reflecting the country’s fast biotech progress.’ 
  • HR Dive tells us,
    • “The U.S. Department of Labor announced a final rule Thursdayupdating its independent contractor classification standard under the Fair Labor Standards Act.
    • “The final rule retains much of DOL’s February proposed rule and is centered on a multifactor “economic reality” test that weighs two core factors: a worker’s degree of control over their work, and their opportunity for profit or loss based on initiative, investment or both. Other “less probative” factors may be considered in the analysis.
    • “In a press conference, Secretary of Labor Keith Sonderling said the rule would provide greater clarity to both workers and employers. DOL’s announcement fulfills a high-priority regulatory project of the second Trump administration, and it is a continuation of a longstanding back-and-forth between Republican and Democratic presidencies.”

From the U.S. Office of Personnel Management front,

  • Tammy Flanagan, writing in Govexec, explains why
    • “Your 2027 federal benefits could cost you more. Here’s what to check now.
      • “A new FSA card, higher Medicare costs and another long-term care insurance freeze make this year’s Open Season especially important. Here’s what to know before Dec. 14.”
  • OPM released four rules today:
    • Fair Labor Standards Act Claims and Compliance
      • Filed on: 11/19/2026 at 8:45 am Scheduled Pub. Date: 11/20/2026 FR Document: 2026-23730 PDF 14 Pages (143 KB) Permalink
    • Federal Employees’ Retirement System: Present Value Conversion Factors for Spouses of Deceased Separated Employees
      • Filed on: 11/19/2026 at 8:45 am Scheduled Pub. Date: 11/20/2026 FR Document: 2026-23729 PDF 7 Pages (96.4 KB) Permalink
    • Procedures for Settling Claims
      • Filed on: 11/19/2026 at 8:45 am Scheduled Pub. Date: 11/20/2026 FR Document: 2026-23731 PDF 10 Pages (133 KB) Permalink
    • Updates and Amendments to the Civil Service Rules
      • Filed on: 11/19/2026 at 8:45 am Scheduled Pub. Date: 11/20/2026 FR Document: 2026-23732 PDF 8 Pages (105 KB) Permalink

From the U.S. Food and Drug Adminstration front,

  • MedPage Today reports,
    • “The FDA approved subcutaneous cemdisiran (Livsayis), a small interfering RNA (siRNA) therapy, to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody-positive, Regeneron announced Wednesday.
    • “Cemdisiran targets complement component 5 (C5), inhibiting terminal complement activation, a key driver of AChR-positive myasthenia gravis. It is the first approved siRNA therapy for myasthenia gravis.
    • “The drug is the second C5 inhibitor the FDA has authorized to treat myasthenia gravis in a week, following the agency’s approval of gefurulimab (Klygefa) last Friday.
  • Multiple Sclerosis Today adds,
    • “The U.S. Food and Drug Administration (FDA) has cleared Neurogenesis Bio to provide its experimental stem cell therapy NG01 to people with progressive forms of multiple sclerosis (MS) through an expanded access program (EAP).
    • “The program, which will allow certain patients unable to participate in the company’s clinical trials to receive the investigational treatment, will initially launch at the University of Miami, with additional U.S. sites expected to follow.
    • “The first patient has been screened and was scheduled to undergo bone marrow aspiration, the first step in manufacturing the treatment, this week.
    • “The FDA’s clearance to proceed is a pivotal step for patients with Progressive MS who have limited treatment options,” Guy Bar-Klein, PhD, Neurogenesis’ senior vice president of clinical and strategy, said in a company press release. “Expanded access allows us to responsibly extend NG01 to patients outside of our trials while we continue to advance the program toward approval.”

No Surprises Act News

  • Per an AHIP news release,
    • “Recent reporting from Axios, The Atlantic and STAT, along with new research from Georgetown University, underscores how some out-of-network providers and private equity-backed entities relentlessly abuse the No Surprises Act’s arbitration (IDR) process — maximizing their own profits by driving up healthcare costs for employers and consumers.” 

From the public health and medical / Rx research front,

  • Beckers Clinical Leadership reports,
    • “Days after the U.S. lost its measles elimination status, which it received in 2000, Pennsylvania officials reported in a Nov. 18 news release the state’s eighth measles-associated death in 2026. 
    • “Wisconsin officials have reported two measles-related deaths, and New York has one. Wisconsin and New York did not disclose vaccination status, but Pennsylvania officials have said the eight deaths were among unvaccinated individuals. 
  • and
    • “The number of influenza cases is climbing earlier than usual, and with at-home flu tests muddying positivity data, health systems are watching multiple metrics to gauge when the worst is to come. 
    • “The data points clinical leaders are watching include emergency department volumes, ICU admissions, capacity dashboards and wastewater. 
    • “As of the week ending Nov. 7, U.S. hospitals reported 9,584 lab-confirmed flu admissions, more than seven times the 1,268 reported during the same surveillance week last season, according to the CDC. Clinical laboratories counted an 11.3% positivity rate among flu tests. At-home flu tests might obscure the true number of positive flu tests.” 
  • Health Day relates,
    • “Young adults struggling with depression, anxiety and stress can do themselves a favor by cutting back on social media, a new study says.
    • “People between 18 and 24 with mood problems who switched to infrequent social media use wound up with a healthier mental state, researchers reported Nov. 16 in JAMA Pediatrics.
    • “The findings suggest that reducing social media use may represent a modifiable target for prevention and early intervention in young adults with elevated symptoms and frequent use,” concluded the research team led by Dae-Hee Han, an assistant professor of behavioral, social and health education sciences at Emory University in Atlanta.”
  • MedPage Today tells us,
    • “Higher circulating eosinophil levels predicted significantly better recurrence-free and distant metastasis-free survival in hormone receptor (HR)-positive/HER2-negative breast cancer.
    • “Higher eosinophil counts identified HR-positive/HER2-negative breast cancer patients who derived greater benefit from CDK4/6 inhibitors.
    • “Eosinophil counts added to prognostic information provided by existing methods”.
  • Medscape informs us,
    • “Among more than 20,000 patients who had taken semaglutide or tirzepatide, those who went on to pursue bariatric surgery, though the least likely choice, had the greatest weight loss after 2 years, while those who stopped treatment altogether had the least, new data show.
    • “To our knowledge, this is the first study to compare weight change and cardiometabolic parameters across several obesity treatment strategies in patients who initially took injectable semaglutide or tirzepatide for obesity or type 2 diabetes,” Hamlet Gasoyan, DS, PhD, MPH, assistant professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Ohio, told Medscape Medical News.  
    • “Our results could support patient–clinician discussions about alternative therapy options in patients who consider switching or stopping these medications,” Gasoyan said of the study, presented at Obesity Week and simultaneously published in eClinicalMedicine.“
  • The New York Times points out,
    • “Each cell in your body is a living world.
    • “Its surface, crammed with sensors and channels, envelopes a stew of billions of molecules. It is continually reconstructing itself, assembling new molecules in thousands of forms, encoded by genes located on long ribbons of DNA in its nucleus.
    • “Each type of cell uses a different combination of genes to carry out its particular tasks — to sprout hair, battle viruses, generate a dream.
    • “Scientists have been charting the cellular world for two centuries. But for all that effort, they have only managed to paint the cell’s portrait in broad strokes. Great mysteries remain within its tiny volume.
    • “Now a growing number of scientists believe artificial intelligence can lift the curtain on many of the cell’s remaining secrets. Researchers are training A.I. models using vast troves of biological data in hopes of creating what is sometimes called a virtual cell: a computer model so realistic that it predicts how any kind of cell will respond to any kind of change.
    • “Different scientists have different dreams for these virtual cells. Some hope they can run experiments on computers that reveal to us how cells function. Others see a place for virtual cells in medical practice.”
  • and
    • “Nearly everyone knows someone living with chronic pain.
    • “Yet this condition remains notoriously difficult to measure, explain or treat. It can follow an acute injury or arrive unprompted, often evading medical scans and leaving patients without the visible evidence that might convince others their pain is real. And doctors still struggle to understand why pain lingers indefinitely in some bodies and dissipates in others.
    • “But a new study, published Thursday in the journal Nature Neuroscience, suggests that some answers could be on the horizon. The analysis — the largest of its kind to date — pooled genetic and health records from more than 1.2 million people across three large biobanks with the aim of mapping the condition’s genetic architecture.
    • “There is no one single “pain gene,” or even a handful of them, said Dr. Stephen Waxman, a neurologist at Yale who studies the genetics of rare pain disorders. (He was not involved in the new study.) Conditions like erythromelalgia, commonly known as “man on fire” syndrome — in which patients feel extreme burning from mild heat sources, like wearing socks — can be driven by a single mutation. But when it comes to common chronic pain, which affects tens of millions of people in the United States alone, thousands of tiny genetic variations interact with environmental factors and one another to influence a patient’s experience.” * * *
    • “The work is still in its foundational stages. Studies of twins and family members have suggested that genes account for about 25 to 50 percent of the variation in chronic pain across a population, but all common genetic variants captured in this analysis still only account for between 5 and 8 percent of that variation. Dr. Henry Kranzler, a professor of psychiatry at the University of Pennsylvania Perelman School of Medicine and one of the study authors, said that with larger and more diverse data sets, the number of known gene variants influencing chronic pain could climb to “what could be 10,000.”
  • Genetic Engineering and Biotechnology News adds,
    • “Research has started to bridge the gap between identifying genetic changes that can increase the risk of brain conditions, such as Alzheimer’s disease (AD), and understanding how they might impact specific cell functions. Researchers at the Wellcome Sanger Institute, Open Targets, and collaborators, differentiated human induced pluripotent stem cells (iPSCs) derived from different donors into microglia-like (iMGL) cells, and showed how genetic variants impact cell behavior, and more specifically, how they can lead to differences in the ability of brain immune cells to move and clear away biological debris.
    • “Through their research the team also used CRISPR gene editing to show how one gene’s effect depends on its cellular context. They found that the impact of a genetic mutation can be completely opposite depending on the precise cell type and its environment, which is highly important for designing future targeted therapies. The study provides an indication of how to connect genetic risk variants with their downstream effects, as a next step in understanding how genes impact health conditions.
    • “Andrew Bassett, PhD, at the Wellcome Sanger Institute and Open Targets, said, “While genetic studies have identified around a hundred genomic regions linked to Alzheimer’s, pinpointing the exact genes involved and how they alter cell behavior has been more of a challenge. By growing brain immune cells from stem cells across hundreds of donors, we’ve built a framework that directly connects genetic risk to real cell functions, such as how effectively these cells clear debris in the brain. We also discovered that the impact of a genetic variant can change depending on its cellular environment, in some cases having the opposite effect. This suggests that we can’t just look at the impact of these genetic changes in isolation or in one cell. Instead, knowing the exact cell context is essential to understanding how these genetic changes impact health.”

From the U.S. healthcare business front,

  • Per an AHIP news release,
    • “A new assessment from Gerard Anderson, a professor at the Johns Hopkins Bloomberg School of Public Health, underscores the affordability challenges created by year-over-year price increases by hospital systems and brand drugmakers and by relentless provider-led abuse of the No Surprises Act’s independent dispute resolution (IDR) process. 
    • “The Root Causes of Higher Premiums: 
      • Rising brand drug prices: Anderson ranks high-priced brand drugs as a key driver of premium growth. Notably, brand drugmakers have raised list prices on 1,284 drugs so far in 2026.
      • Higher hospital prices: Hospitals are the largest single driver of higher premiums, accounting for more than 40 cents of every premium dollar. Even modest hospital price increases often show up in what families and employers pay in their premiums—exacerbated by hospital monopolies which limit competition and raise costs.
      • Provider-led IDR abuse: Certain out-of-network providers and private equity-backed entities are abusing the No Surprises Act’s IDR process to extract outsized payouts. Axios reports that IDR has driven up administrative costs and medical expenses as more providers go out of network, adding to the cost pressures facing small businesses and self-funded employers. Georgetown University researchers estimate IDR spending pushed No Surprises Act costs to more than $22.4 billion from 2022 through 2025. Aetna President Steve Nelson said IDR “has now become a top-three single driver of healthcare cost increases for employers.”
    • “The Bigger Picture: Nearly two-thirds of every premium dollar goes to hospitals and brand drugmakers, whose prices are high and rising far faster than broader inflation. IDR abuse by certain providers, often backed by private equity, adds billions more on top of that. Employers, workers and patients ultimately pay for these costs through higher premiums.
    • Health plans are doing everything in their power to keep coverage and care as affordable as possible. But common-sense bipartisan reforms, such as site-neutral payment for hospitals, ending brand drug patent abuses and stopping provider-driven IDR abuse, are needed to make coverage and care more affordable for Americans.”
  • Beckers Payers Issues reports,
    • “Aetna launched Aetna For You & Baby, a five-year maternal and infant health initiative, Nov. 19. 
    • “By 2032, Aetna aims to have 90% of its expecting mothers and babies connected with end-to-end care, up 30 percentage points. The initiative covers “holistic care” through pregnancy and a child’s first year. Infants receive at least six well-child visits in their first 15 months.
    • “The effort also focuses on prenatal and postpartum physical health, including a prenatal visit in the first trimester and a postpartum visit within 12 weeks of delivery. Maternal mental health is another essential care area. Moms get standardized depression screenings during pregnancy and after delivery.
    • “The program includes early outreach to high-risk mothers, partnerships for timely healthcare access, evidence-based care and guidance for new moms.
    • “Aetna also said Aetna Care Paths, a digital healthcare navigation tool, and Health100, another CVS Health subsidiary with a personal AI health assistant, will play roles in Aetna For You & Baby. Aetna said the resources can help families map out their care journey and understand benefits.”
  • and
    • “Oscar Health and Midwestern grocery chain Hy-Vee are expanding where their health plan is available in 2027.
    • “ACA enrollees and employees with custom health option and individual care expense arrangements can sign up for the Hy-Vee Health with Oscar plan across all of Iowa, as well as in parts of the Kansas City and Omaha metro areas. The 2027 open enrollment period began Nov. 1 and runs through Jan. 15. 
    • “Hy-Vee has been a joint owner of direct primary care practice Exemplar Care since 2024 and rebranded it as Hy-Vee Health Exemplar Care. The practice has more than 17 clinic locations across the region, and the plan includes free care at the clinics. 
    • “The plan also includes $50 in Hy-Vee rewards, and prescriptions are available at the store’s pharmacies. Iowa, Kansas City and Omaha members each have access to at least two health systems.”
  • Beckers Hospital Review relates,
    • “Operating margins at health systems widely varied in the third quarter of 2026. For-profit operators led the group, while a handful of systems slipped into the red.
    • “Tenet Healthcare saw the highest operating margin, 31.1%, on $5.6 billion in revenue, and HCA Healthcare saw an 11.9% margin on $19.8 billion in revenue. Among nonprofits, BayCare Health System (11.3%) and WVU Health System (9.6%) led the pack, followed by Mayo Clinic (7%) and Cleveland Clinic (6.5%).
    • “Kaiser Permanente brought in the most revenue of any system ranked, at $34.7 billion, but its operating margin was 1.4%. Providence barely stayed in the black with a 0.1% margin. Allegheny Health Network and Altru Health System both posted operating losses, each with a -3% margin.
    • “[The article ranks] 20 health systems by their Q3 operating margins.”
  • and
    • “Dallas-based Children’s Health reported an operating income of $168.2 million (6.5% margin) in the third quarter of 2026, ending Sept. 30, down from a $253.3 million (10.3% margin) in fiscal 2025, according to a Nov. 19 financial report.”
  • HCPLan notes,
    • “Today the Health Care Payment Learning & Action Network (HCPLAN) released the Applying the Evidence-Based Prevention Continuum: Advancing Health and Value Through Nutrition-Focused Interventions, a brief designed to help payers and funders use evidence to inform decisions about nutrition interventions delivered through or connected to the health care system. 
    • “Developed for public and private payers, research funders, investors, and other health care stakeholders, the brief addresses a key challenge: despite emerging evidence that certain nutrition interventions can improve chronic condition outcomes and reduce associated hospitalizations, there is a lack of consensus about when and how to invest in, test, evaluate, and scale these interventions. 
    • “The brief builds on HCPLAN’s Evidence-Based Prevention Continuum, a framework for advancing evidence generation and implementing evidence-based preventive interventions as part of permanent care delivery and payment models. The Continuum provides a shared language for matching the strength of available evidence to an appropriate level of action. Using the Continuum, the brief helps payers and funders distinguish between interventions that may be ready for broad integration into health care coverage; appropriate for targeted pilots or specific populations while additional evidence is developed; or require further evidence generation before broader scaling.” * * *
    • “The Applying the Evidence-Based Prevention Continuum: Advancing Health and Value Through Nutrition-Focused Interventions brief is available here.”
  • Healthcare Dive informs us,
    • “Elsevier unveiled this week a major upgrade to ClinicalKey AI, enabling the AI-powered clinical decision support tool to access a patient’s full electronic health record and evaluate treatment plans against the company’s evidence-based medical library.
    • “As AI advances, Elsevier has strategically shifted from a traditional academic publisher—it’s one of the world’s largest publishers of scientific, technical and medical content—to an AI-driven analytics information company, incorporating generative and agentic AI into its healthcare and academic research.
    • “ClinicalKey AI is a HIPAA-ready point-of-care decision support tool that draws answers from full-text articles from approximately 1,000 world-leading journals. Elsevier’s upgraded ClinicalKey AI is already deployed at more than 1,200 hospitals, and the company says the solution integrates with all electronic health record providers. Elsevier recently struck a content agreement with the JAMA Network that brings full-text content and visuals from the JAMA Network Family of Journals to ClinicalKey AI.”
  • and
    • “Americans want a healthcare experience that’s simpler and easier to understand, and artificial intelligence may be the key to getting there, a new survey shows.
    • “The poll, conducted by the Harris Poll and commissioned by Elevance Health, found that 82% of American patients view at least some part of healthcare information as a “foreign language,” and close to half (45%) said they made a healthcare decision they later regretted due to a lack of understanding.
    • “The survey was conducted among 2,0001 adults in mid-July, and 74% said they have encountered a key barrier, such as understanding their health insurance or a medical bill. And only a quarter (27%) said they completely understand their own health coverage.”
  • Per the Wall Street Journal,
    • “Novartis projected steady sales growth over the next five years to reassure investors ahead of upcoming patent expirations.
    • “The Swiss drugmaker forecast annual sales growth of 5% from 2026 to 2031, excluding currency effects.
    • “CEO Vas Narasimhan said Novartis is deploying AI to conduct clinical trials faster and with a higher probability of success.”

Leave a Reply

Your email address will not be published. Required fields are marked *